s.
Warnings/Precautions:
For intralesional inj only. Avoid accidental exposure (esp. skin, eyes, mucous membranes) and direct contact with patient's injected lesions, dressings, or body fluids. Advise patients to avoid inadvertent transfer of drug to other areas of the body (eg, touching/scratching inj sites or occlusive dressings). eva luate lesions if suspected herpetic infection occurs. Inj site complications (eg, necrosis or ulceration of tumor tissue, cellulitis, systemic bacterial infection). Persistent infection or delayed healing of inj site. Underlying autoimmune disease. Multiple myeloma or plasmacytoma. Pregnancy. Women of childbearing potential should use effective method of contraception. Nursing mothers: not recommended.
Interactions:
Acyclovir or other antiherpetic viral agents may interfere with efficacy.
Pharmacological Class:
Genetically modified oncolytic viral therapy.
Adverse Reactions:
Fatigue, chills, pyrexia, nausea, influenza-like illness, inj site pain; immune-mediated events.
Note:
Report suspected herpetic lesions to Amgen at (855) 465-9442.
Generic Availability:
NO
How Supplied:
Single-use vial (1mL)—1 |
